Lite Strategy’s Fragile Rally Highlights Risky Biotech Future Amid Market Volatility
Lite Strategy’s $1.24 share shows a brief uptick, yet a $35M cap, low liquidity, and no clinical milestones leave investors wary of a fragile future in cancer metabolism.
- LITE STRATEGY INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read